Decision Support Service · UK public procurement notice

CPV: System and support services

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Services

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

20 Nov 2024, 11:23 GMT

Last source update

20 Nov 2024, 11:23 GMT

Authority reference

GeL-17/02

FTS notice number

2024/S 000-037488

Classification (CPV)

System and support services

Delivery area

London (UKI)

Official registry OCID

ocds-h6vhtk-04bd2f Find a Tender

Why no open competition

The procurement falls outside the scope of application of the directive

Published justification

Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.

Publisher note: Genomics England will on 1 December 2024 enter into a contract amendment for the Decision Support Service Contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months with an option to extend for a further 6 + 6 months. Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract. NHS England has confirmed that a functioning decision support system for rare disease is essential to the success of the GMS for rare disease and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System (NGIS) pipeline and no off the shelf product is available or viable without significant development. Given the background to Congenica development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. Genomics England are in the process of developing a replacement solution.

• CongenicaAwarded supplier Wellcome Genome Campus, Cambridge, East of England, CB10 1DR

No document links were published on the notice.